Emtricitabine / rilpivirine / tenofovir alafenamide Oral Tablet
RxNorm 1741732

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1741732 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: emtricitabine / rilpivirine / tenofovir alafenamide Oral Tablet.

The following semantic concepts and normalized strings are associated with this clinical entity:

SCDF
Emtricitabine / rilpivirine / tenofovir alafenamide Oral Tablet
AUI:12263087
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SCDFPrescribable

Semantic Clinical Drug Form (SCDF):
Emtricitabine / rilpivirine / tenofovir alafenamide Oral Tablet
(Atom ID: 12263087)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
emtricitabine / rilpivirine / tenofovir alafenamide Oral Tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1741732
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12263087
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCDF
Semantic Clinical Drug Form (Ingredient + Dose Form)
Source Code
1741732
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Emtricitabine, Rilpivirine, and Tenofovir


The combination of emtricitabine, rilpivirine, and tenofovir is used to treat HIV in adults and children who weigh at least 77 pounds (35 kilograms). Emtricitabine, rilpivirine, and tenofovir are in a class of medications called nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs). They work by slowing the spread of HIV in the body. Although emtricitabine, rilpivirine, and tenofovir will not cure HIV, these medications may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of getting or transmitting the HIV virus to other people.
[Learn More]


* Please review the disclaimer below.